Inactive Instrument

News Imago BioSciences, Inc.

Equities

IMGO

US45250K1079

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Merck Completes Tender Offer to Acquire Imago BioSciences, Inc	23-01-12	AQ
Imago BioSciences : Acquisition/Asset Disposal - Form 8-K	23-01-11	PU
IMAGO BIOSCIENCES, INC. : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	23-01-11	AQ
Imago BioSciences, Inc. Announces Board Changes	23-01-11	CI
Merck & Company Concludes Cash Tender Offer to Acquire Imago BioSciences	23-01-11	MT
Imago BioSciences, Inc.(NasdaqGS:IMGO) dropped from NASDAQ Composite Index	23-01-11	CI
Imago BioSciences, Inc.(NasdaqGS:IMGO) dropped from S&P Global BMI Index	23-01-11	CI
Imago BioSciences, Inc.(NasdaqGS:IMGO) dropped from S&P TMI Index	23-01-11	CI
Merck Sharp & Dohme Corp. completed the acquisition of Imago BioSciences, Inc..	23-01-10	CI
Insider Sell: Imago Biosciences	22-12-29	MT
Insider Sell: Imago Biosciences	22-12-29	MT
Insider Sell: Imago Biosciences	22-12-20	MT
Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 2 Study of Bomedemstat in Combination with Ruxolitinib in Myelofibrosis	22-12-20	AQ
Imago BioSciences, Inc. Announces First Participant Dosed in Investigator-Sponsored Phase 2 Study of Bomedemstat in Combination with Ruxolitinib in Myelofibrosis	22-12-20	CI
Insider Sell: Imago Biosciences	22-12-19	MT
Insider Sell: Imago Biosciences	22-12-19	MT
Imago BioSciences, Inc.(NasdaqGS:IMGO) dropped from NASDAQ Biotechnology Index	22-12-16	CI
Imago BioSciences Reports 'Positive' Mid-Stage Results in Thrombocythemia Trial	22-12-12	MT
IMAGO BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	22-12-12	AQ
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2022	22-12-12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Imago BioSciences, Inc.

Equities

IMGO

US45250K1079

Summary

Filters